Role of bicyclol in preventing chemotherapeutic agent-induced liver injury in patients over 60 years of age with cancer

Objective To evaluate the efficacy of bicyclol in preventing chemotherapy-induced liver damage. Methods Patients ≥60 years of age with cancer were equally randomized into control (chemotherapy alone) or prophylactic (chemotherapy supplemented with 75 mg bicyclol, oral, daily) groups. Liver function indices were assessed immediately before treatment, during each therapy cycle and following treatment. Results Of 306 patients enrolled, 300 patiets completed the study (n = 147 and n = 153; prophylactic and control groups, respectively). Incidence of grade I–IV elevation of serum transaminase and/or bilirubin was significantly lower in the prophylactic group (17.1%) compared with the control group (47.1%). Incidence of grade II–IV hepatic injury was also significantly lower in the prophylactic group (0.7%) than in the control group (12.4%). Conclusions Prophylactic bicyclol (75 mg daily) could significantly reduce the incidence and degree of chemotherapeutic agent-induced liver damage in elderly patients with cancer. Further studies are recommended with larger sample sizes and long-term follow up.

[1]  Qin Ni,et al.  [Efficacy of combination therapy with peginterferon alfa-2alpha and bicyclol in chronic hepatitis B with high ALT levels]. , 2012, Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology.

[2]  Z. Fan,et al.  [The clinical efficacy and safety of adefovir dipivoxil in combination with bicyclol for the treatment of senior patients with chronic hepatitis B]. , 2011, Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology.

[3]  B. Vincenzi,et al.  The role of S-adenosyl methionine in preventing FOLFOX-induced liver toxicity: a retrospective analysis in patients affected by resected colorectal cancer treated with adjuvant FOLFOX regimen , 2011, Expert opinion on drug safety.

[4]  Chen Rui Effect of tiopronin in the prevention and treatment of the hepatotoxicity caused by anti-tumor agents in cancer patients , 2011 .

[5]  M. Büchler,et al.  Dietary glycine protects from chemotherapy-induced hepatotoxicity , 2011, Amino Acids.

[6]  B. Vincenzi,et al.  The role of S-adenosylmethionine in preventing oxaliplatin-induced liver toxicity: a retrospective analysis in metastatic colorectal cancer patients treated with bevacizumab plus oxaliplatin-based regimen , 2010, Supportive Care in Cancer.

[7]  A. Zhu,et al.  Hepatic toxicities associated with the use of preoperative systemic therapy in patients with metastatic colorectal adenocarcinoma to the liver. , 2009, The oncologist.

[8]  Y. Li,et al.  Effect of bicyclol on cisplatin-induced hepatotoxicity in the hepatocarcinoma 22 tumour-bearing mice. , 2009, Basic & clinical pharmacology & toxicology.

[9]  Geng-tao Liu Bicyclol: a novel drug for treating chronic viral hepatitis B and C. , 2009, Medicinal chemistry (Shariqah (United Arab Emirates)).

[10]  J. Buckels,et al.  Effect of preoperative chemotherapy on liver resection for colorectal liver metastases. , 2008, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[11]  B. Ruan,et al.  [Comparison of bicyclol therapy for patients with genotype B and C of hepatitis B virus]. , 2007, Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology.

[12]  J. Senior,et al.  Drug-related hepatotoxicity. , 2006, The New England journal of medicine.

[13]  A. Naeim,et al.  Physiologic Aspects of Aging: Impact on Cancer Management and Decision Making, Part II , 2005, Cancer journal.

[14]  A. Naeim,et al.  Physiologic Aspects of Aging: Impact on Cancer Management and Decision Making, Part I , 2005, Cancer journal.

[15]  B. Vincenzi,et al.  S-adenosylmethionine (AdoMet) supplementation for treatment of chemotherapy-induced liver injury. , 2003, Anticancer research.

[16]  G. Rosner,et al.  Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  L. Norton,et al.  Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Zimmerman Hj,et al.  Morphologic spectrum of drug-induced hepatic disease. , 1995 .

[19]  W. M. Lee,et al.  Drug-induced hepatotoxicity. , 1995, The New England journal of medicine.

[20]  N. Dobbs,et al.  Clinical efficacy and toxicity of standard dose adriamycin in hyperbilirubinaemic patients with hepatocellular carcinoma: relation to liver tests and pharmacokinetic parameters. , 1992, British Journal of Cancer.